Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	23.56	25.66	18.59	39.65	27.14	47.48
Cash & Cash Equivalents	23.56	25.66	18.59	39.65	27.14	47.48
Cash Growth	32.34%	38.02%	-53.11%	46.08%	-42.83%	475.31%
Other Current Assets	1.91	2.05	1.96	2.17	2.32	0.73
Total Current Assets	25.46	27.71	20.55	41.82	29.47	48.21
Other Long-Term Assets	0.43	0.49	0.73	0.01	0.14	0.26
Total Long-Term Assets	0.43	0.49	0.73	0.01	0.14	0.26
Total Assets	25.89	28.2	21.29	41.83	29.6	48.47
Accounts Payable	3.8	6.49	3.95	1.87	1.36	1.73
Other Current Liabilities	8.84	9.18	9.06	7.16	4.04	1.09
Total Current Liabilities	12.63	15.68	13.01	9.03	5.4	2.82
Long-Term Debt	82.46	71.74	39.83	29.05	0	0
Other Long-Term Liabilities	1.88	1.02	0.64	1.13	0.01	0.05
Total Long-Term Liabilities	84.34	72.77	40.47	30.18	0.01	0.05
Total Liabilities	96.98	88.44	53.48	39.21	5.41	2.87
Total Debt	82.46	71.74	39.83	29.05	0	0
Debt Growth	65.12%	80.13%	37.11%	-	-	-
Retained Earnings	-365.87	-354.37	-309.57	-270.69	-240	-216.39
Shareholders' Equity	-72.81	-61.96	-33.92	0.89	22.47	43.87
Net Cash / Debt	-58.91	-46.08	-21.24	10.6	27.14	47.48
Net Cash / Debt Growth	-	-	-	-60.95%	-42.83%	475.31%
Net Cash Per Share	-0.95	-0.77	-0.36	0.18	0.48	0.91
Working Capital	12.83	12.03	7.54	32.79	24.07	45.39
Book Value Per Share	-1.18	-1.03	-0.57	0.01	0.39	0.84

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).